SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Long-Acting Muscarinic Antagonist (LAMA) Anticholinergic inhalers

Drug Requested: (Select one from below)

❑ **Tudorza® Pressair®** (aclidinium bromide inhalation powder)	❑ **Yupelri®** (revefenacin) **oral inhalation solution**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight: _____ **Date:** _____

Quantity Limits:

- **Tudorza® Pressair® - 1 inhaler per 30 days**
- **Yupelri® - 30 vials per 30 days**

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have tried and failed **at least 30 days** of therapy with **BOTH** of the following medications:
  - ❑ Spiriva® Respimat®

    AND
  - ❑ Incruse® Ellipta®

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee:** 6/21/2018
UPDATED/REVISED/REFORMATTED: 9/29/2018; (Reformatted) 6/21/2019; 6/2/2020; 8/26/2022; ~~10/24/2023~~**, 2/12/2024**